KRONİK BÖBREK YETMEZLİĞİNDE DEMİR EKSİKLİĞİ ANEMİSİNDE DEMİR KARBOKSİMALTOZ TEDAVİSİNİN ETKİNLİĞİ: TEK MERKEZ DENEYİMİ

Giriş: Kronik böbrek yetmezliğinde demir eksikliği anemisi hastalığın mortalitesi ve morbitidesi ile doğrudan ilişkilidir. Bu hastalarda demir tedavisinin intravenöz yoldan uygulanması hem daha hızlı yanıtla oral tedavilere göre üstün hem de güvenilir bir yöntemdir. Çalışmamızda GFR

THE EFFICACY OF FERRIC CARBOXYMALTOSE TREATMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE :A SINGLE CENTER STUDY

Introduction: In chronic kidney disease (CKD) , iron deficiency anemia is directly related to the mortality and morbidity of the disease. Intravenous administration of iron therapy for these patients is both superior with more rapid response compared to oral treatments and is a reliable method. In our study, we aimed to share the results of IV ferric carboxymaltose treatment in our advanced stage CKD cases at predialysis and dialysis with GFR

PDF

___

World Health Organization. Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers 2001; 47-62.
Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67(6): 2089- 100.
Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: Behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 2014; 85(1): 49-61.
Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13(2): 504-10.
Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a communitybased population. JAMA 2004; 291(7): 844-50.
he International Society of Nephrology . Diagnosis and evaluation of anemia in CKD. Kidney Int Suppl 2012; 2(4): 288- 91.
Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (Suppl. 2):i1-47.
Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50(5): 1694–9.
Li H, Wang SX. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif 2008; 26(2): 151– 6.
Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara C, et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 2004; 19(6): 655–61.
Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S.A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68(6): 2846–56.
Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D et al.FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29 (11): 2075–84.
Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88(4): 905–14.
Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17(8): 2275-84.
Süleymanlar G, Utaş C, Arinsoy T, Ateş K, Altun B, Altiparmak MR, et al. A population based survey of chronic renal disease in Turkey – The CREDIT study. Nephrol Dial Transplant 2011; 26(6): 1862-71.
Rocha LA, Barreto DV, Barreto FC, Dias CB, Moysés R, Silva MR, et al. Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4(1): 105- 9.
Goddard AF, James MW, Mc Intyr AS, Scott BB. Guidelines for the management of iron deficiency anemia. Gut 2011; 60(10): 1309-16.
Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23(10):1631-4.
Fernández-Rodríguez AM, Guindeo-Casasús MC, Molero-Labarta T, Domínguez-Cabrera C, Hortal-Casc n L, PérezBorges P, et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 1999; 34(3): 508-13.
Roger SD, Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, et al. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. Nephrol Dial Transplant 2017; 32(9): 1530-9.
Rozen Zvi B, Gafter Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta analysis. Am J Kidney Dis 2008; 52(5): 897–906.
Brookhart MA, Freburger JK, Ellis AR, Winkelmayer WC, Wang L, Kshirsagar AV. Comparative short-term safety of sodium ferric gluconate versus iron sucrose in hemodialysis patients. Am J Kidney Dis 2016; 67(1): 119–27.
Freburger JK, Ellis AR, Wang L, Butler AM, Kshirsagar AV, Winkelmayer WC, et al. Comparative effectiveness of iron and erythropoiesis-stimulating agent dosing on health-related quality of life in patients receiving hemodialysis. Am J Kidney Dis 2016; 67(2): 271–82.